Molecular Pathways and Targeted Therapies for Malignant Ovarian Germ Cell Tumors and Sex Cord–Stromal Tumors: A Contemporary Review
Open Access
Abstract
Non-epithelial ovarian tumors are heterogeneous and account for approximately 10% of ovarian malignancies. The most common subtypes of non-epithelial ovarian tumors arise from germ cells or sex cord and stromal cells of the gonads. These tumors are usually detected at an early stage, and management includes surgical staging and debulking. When indicated for advanced disease, most respond to chemotherapy; however, options for patients with refractory disease are limited, and regimens can be associated with significant toxicities, including permanent organ dysfunction, secondary malignancies, and death. Targeted therapies that potentially decrease chemotherapy-related adverse effects and improve outcomes for patients with chemotherapy-refractory disease are needed. Here, we review the molecular landscape of non-epithelial ovarian tumors for the purpose of informing rational clinical trial design. Recent genomic discoveries have uncovered recurring somatic alterations and germline mutations in subtypes of non-epithelial ovarian tumors. Though there is a paucity of efficacy data on targeted therapies, such as kinase inhibitors, antibody–drug conjugates, immunotherapy, and hormonal therapy, exceptional responses to some compounds have been reported. The rarity and complexity of non-epithelial ovarian tumors warrant collaboration and efficient clinical trial design, including high-quality molecular characterization, to guide future efforts.Keywords
Funding Information
- Ensign Endowment for Gynecologic Cancer Research (n/a)
- National Cancer Institute (CA217685)
- American Cancer Society (n/a)
- Frank McGraw Memorial Chair in Cancer Research (n/a)
This publication has 162 references indexed in Scilit:
- Molecular Characteristics of Malignant Ovarian Germ Cell Tumors and Comparison With Testicular Counterparts: Implications for PathogenesisEndocrine Reviews, 2013
- FOXL2 molecular testing in ovarian neoplasms: diagnostic approach and procedural guidelinesLaboratory Investigation, 2013
- Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2012
- Residual tumor after the salvage surgery is the major risk factors for primary treatment failure in malignant ovarian germ cell tumors: A retrospective study of single institutionWorld Journal of Surgical Oncology, 2011
- Ovarian sex cord-stromal tumors, pleuropulmonary blastoma and DICER1 mutations: A report from the International Pleuropulmonary Blastoma RegistryGynecologic Oncology, 2011
- Patterns of spread and recurrence of sex cord-stromal tumors of the ovaryGynecologic Oncology, 2011
- Prognostic impact of lymphadenectomy in clinically early stage malignant germ cell tumour of the ovaryBritish Journal of Cancer, 2011
- Aromatase Is a Direct Target of FOXL2: C134W in Granulosa Cell Tumors via a Single Highly Conserved Binding Site in the Ovarian Specific PromoterPLOS ONE, 2010
- Comprehensive Staging Allows for Excellent Outcome in Patients With Localized Malignant Germ Cell Tumor of the OvaryAnnals of Surgery, 2008
- FSH signaling pathways in immature granulosa cells that regulate target gene expression: Branching out from protein kinase ACellular Signalling, 2006